No Picture
News

Molecular Stethoscope Announces Completion and Publication of its Alzheimer’s Disease Study in Science Advances

Study results highlight the Company’s Next-Generation cf-mRNA Liquid Biopsy-Artificial Intelligence Technology Platform for characterization of Alzheimer’s Disease

PALO ALTO, Calif., Dec. 14, 2020 /PRNewswire/ — Molecular Stethoscope, Inc., a precis… […]

No Picture
News

Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML

SAN DIEGO, Dec. 6, 2020 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cance… […]

No Picture
News

Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting

Data from ongoing Phase 1 expansion trial using nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile

SAN DIEGO, Dec. 5, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (NASDAQ:PSTX),… […]

No Picture
News

Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting

Data from ongoing Phase 1 expansion trial using nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile

SAN DIEGO, Dec. 5, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (NASDAQ:PSTX),… […]

No Picture
News

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

– Disease control observed in 92% of patients- Conference call to be held today at 2:30pm PT

SAN DIEGO, Nov. 11, 2020 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated … […]

No Picture
News

New case study shows virtual reality tools could save biopharmaceutical companies tens of thousands per year

SAN DIEGO, Nov. 2, 2020 /PRNewswire/ — In a case study released October 23 by Oculus for Business from Facebook, Nimbus Therapeutics explains why they expect to save tens of thousands of dollars per year by investing in virtual reality (VR) hardwar… […]

No Picture
News

Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance

— Trial on track to meet prespecified criteria for success on its primary endpoint, with 31% (8/26) disease control rate in evaluable patients in cohorts A and B. Patients eligible for the trial have two consecutive rises in PSA levels indicating init… […]

No Picture
News

Neurelis Announces Four Poster Presentations For The Joint Meeting Of The International Child Neurology Association And Child Neurology Society

– Data continue to support the unique clinical attributes for Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and … […]

No Picture
News

HUYA Bioscience International Submits HBI-8000 Monotherapy for Adult T-cell Leukemia/Lymphoma for Regulatory Approval in Japan

SAN DIEGO, Oct. 6, 2020 /PRNewswire/ — HUYA Bioscience International (HUYABIOTM ), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the submission of a regulatory application to the Japanese Pharm… […]

No Picture
News

Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

– Over 90% of Hernia Repair Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 hours After Surgery –

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biote… […]